Penumbra Inc (PEN) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Penumbra Inc  (NYSE: PEN)


Penumbra Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Penumbra Inc's ROI in the second quarter of 2026?
Penumbra Inc achieved a return on average invested assets (ROI) of 9.67 % in its second quarter of 2026, this is above PEN's average return on investment of 2.94%.
Penumbra Inc invested over the 12 months ending in its second quarter of 2026 $1,661 million

ROI fell compared to the first quarter of 2026, despite the net income growth of 6.83% from the first quarter of 2026.

Within the Healthcare sector 114 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 762 to 871.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 17.57 % 16.36 % 11.95 % 6.49 % 2.05 %
Y / Y Net Income Change TTM 8.72 % 305.01 % 5803.22 % - -
Investment (TTM) in Millions 1,741 1,687 1,643 1,575 1,517
Return On Investment (TTM) 9.67 % 10.65 % 11.52 % 11.12 % 10.45 %
PEN's Overall Ranking # 871 # 762 # 575 # 598 # 158
Seq. Investment Change TTM 3.49 % 4.08 % 4.55 % 4.4 % 2.42 %
Seq. Net Income Change TTM -6.11 % -3.74 % 8.33 % 11.05 % 249.73 %
Net Income (TTM) in Millions 161 171 178 164 148

PEN Company Profile >> Back to PEN Roi Comparisons >> See Annual PEN Return On Investment



Return On Investment PEN's Ranking
Within: No.
Industry # 37
Sector # 115
Overall # 871

Return On Investment Statistics
High Average Low
10.3 %
2.94 %
-2.73 %
(Dec 31 2025)   (Dec 31 2020)







Financial Statements
Penumbra Inc's II. Quarter Investments $ 1,741 Millions PEN's Balance sheet
Penumbra Inc's II. Quarter Income $ 35 Millions Quarterly PEN's Income Statement
PEN's Income by Division See PEN's Income by Division


PEN Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,643 1,375 1,405 1,226 1,121
Y / Y Investment Growth 19.53 % -2.16 % 14.62 % 9.36 % 57.16 %
Net Income in Millions 178 14 91 -2 3
Y / Y Net Income Growth 1168.11 % -84.59 % - - -
Annual Return On Investment 10.81 % 1.02 % 6.47 % -0.16 % 0.23 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 10.81 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PEN's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PEN's Competitors
Subscribers only: Roi for Penumbra Inc's Suppliers
Subscribers only: Return On Investment for PEN's Customers

Other Ratios
PEN's Roa PEN's Inventory Turnover Ratio PEN's Growth Rates PEN's Dividend Statistics
PEN's Profitability Ratios PEN's Asset Turnover Ratio PEN's Dividend Growth
PEN's Roe PEN's Valuation Ratios PEN's Financial Strength Ratios PEN's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %
Theravance Biopharma inc   17.10 %
Standard Biotools Inc   16.38 %
Inspire Medical Systems inc   16.34 %
Aveanna Healthcare Holdings Inc   16.32 %
Harmony Biosciences Holdings inc   15.85 %
Entera Bio Ltd   15.84 %

Date modified: 2026-09-14T03:59:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.